Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Trial Profile

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Furosemide (Primary) ; Furosemide
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms FREEDOM-HF
  • Sponsors scPharmaceuticals
  • Most Recent Events

    • 07 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Jul 2021.
    • 07 Nov 2019 Planned primary completion date changed from 1 Mar 2020 to 1 May 2021.
    • 07 Nov 2019 Planned initiation date changed from 1 Jun 2019 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top